These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 31302695

  • 21. Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data.
    Wallace DJ, Atsumi T, Daniels M, Hammer A, Meizlik P, Quasny H, Schwarting A, Zhang F, Roth DA.
    Lupus; 2022 Nov; 31(13):1649-1659. PubMed ID: 36206400
    [Abstract] [Full Text] [Related]

  • 22. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
    Furie R, Rovin BH, Houssiau F, Contreras G, Teng YKO, Curtis P, Green Y, Okily M, Madan A, Roth DA.
    Clin J Am Soc Nephrol; 2022 Nov; 17(11):1620-1630. PubMed ID: 36302567
    [Abstract] [Full Text] [Related]

  • 23. Belimumab for systemic lupus erythematosus.
    Singh JA, Shah NP, Mudano AS.
    Cochrane Database Syst Rev; 2021 Feb 25; 2(2):CD010668. PubMed ID: 33631841
    [Abstract] [Full Text] [Related]

  • 24. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec 25; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 25. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
    Bae SC, Bass DL, Chu M, Curtis P, Dimelow R, Harvey L, Ji B, Kurrasch R, Muzaffar S, Punwaney R, Roth DA, Song YW, Xie W, Zhang F.
    Arthritis Res Ther; 2022 Feb 16; 24(1):46. PubMed ID: 35172878
    [Abstract] [Full Text] [Related]

  • 26. EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus.
    Lindblom J, Gomez A, Borg A, Emamikia S, Ladakis D, Matilla J, Pehr M, Cobar F, Enman Y, Heintz E, Regardt M, Parodis I.
    Rheumatology (Oxford); 2021 Oct 02; 60(10):4703-4716. PubMed ID: 33502473
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
    Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Struemper H, Roth D.
    Mod Rheumatol; 2019 May 02; 29(3):452-460. PubMed ID: 29792370
    [Abstract] [Full Text] [Related]

  • 28. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial.
    Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, Calderon JE, Chasnyk VG, Ferrandiz MA, Keltsev V, Paz Gastanaga ME, Shishov M, Boteanu AL, Henrickson M, Bass D, Clark K, Hammer A, Ji BN, Nino A, Roth DA, Struemper H, Wang ML, Martini A, Lovell D, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Ann Rheum Dis; 2020 Oct 02; 79(10):1340-1348. PubMed ID: 32699034
    [Abstract] [Full Text] [Related]

  • 29. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D.
    Lupus; 2016 Apr 02; 25(4):346-54. PubMed ID: 26385220
    [Abstract] [Full Text] [Related]

  • 30. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.
    Oon S, Huq M, Golder V, Ong PX, Morand EF, Nikpour M.
    Ann Rheum Dis; 2019 May 02; 78(5):629-633. PubMed ID: 30679152
    [Abstract] [Full Text] [Related]

  • 31. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
    van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W.
    Ann Rheum Dis; 2012 Aug 02; 71(8):1343-9. PubMed ID: 22337213
    [Abstract] [Full Text] [Related]

  • 32. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase A, Roth DA, Zhong ZJ, Cooper S, Freimuth WW, Ginzler EM, BLISS-52 and -76 Study Groups.
    Lupus; 2013 Jan 02; 22(1):63-72. PubMed ID: 23263865
    [Abstract] [Full Text] [Related]

  • 33. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.
    Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S, Chatzidionysiou K.
    Rheumatology (Oxford); 2019 Dec 01; 58(12):2170-2176. PubMed ID: 31157891
    [Abstract] [Full Text] [Related]

  • 34. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus.
    Lokhandwala T, Yue B, Coutinho AD, Bell CF.
    Lupus Sci Med; 2021 Feb 01; 8(1):. PubMed ID: 33558436
    [Abstract] [Full Text] [Related]

  • 35. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
    Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, Isenberg DA, Gordon C, Ehrenstein MR.
    BMJ Open; 2019 Dec 16; 9(12):e032569. PubMed ID: 31848169
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2018 Aug 16; 70(8):1256-1264. PubMed ID: 29671280
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia.
    Suh CH, Lee Y, Yoo SB, Quasny H, Navarro Rojas AA, Hammer A, Song YW, Kang YM, Cho CS, Park W, Kwok SK, Lee SG, Chung WT, Bae SC.
    Int J Rheum Dis; 2024 Jan 16; 27(1):e14997. PubMed ID: 38140854
    [Abstract] [Full Text] [Related]

  • 38. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.
    Tanaka Y, Bae SC, Bass D, Curtis P, Chu M, DeRose K, Ji B, Kurrasch R, Lowe J, Meizlik P, Roth DA.
    RMD Open; 2021 Jul 16; 7(2):. PubMed ID: 34215703
    [Abstract] [Full Text] [Related]

  • 39. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Iaccarino L, Bettio S, Reggia R, Zen M, Frassi M, Andreoli L, Gatto M, Piantoni S, Nalotto L, Franceschini F, Larosa M, Fredi M, Punzi L, Tincani A, Doria A.
    Arthritis Care Res (Hoboken); 2017 Jan 16; 69(1):115-123. PubMed ID: 27390293
    [Abstract] [Full Text] [Related]

  • 40. Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.
    Zhang F, Zheng J, Li Y, Wang G, Wang M, Su Y, Gu J, Li X, Bass D, Chu M, Curtis P, DeRose K, Kurrasch R, Lowe J, Meizlik P, Roth DA.
    RMD Open; 2022 Apr 16; 8(1):. PubMed ID: 35428697
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.